Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676–81.

Article  Google Scholar 

Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12:98.

Article  Google Scholar 

Bertamini L, Bertuglia G, Oliva S. Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results. Front Oncol. 2022;12:844779.

Article  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy Bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

CAS  Article  Google Scholar 

Adaniya SPS, Cohen AD, Garfall AL. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications. Am J Hematol. 2019;94:S28–33.

Article  Google Scholar 

Parrondo RD, Sam K, Rasheed A, Alegria V, Sher T, Roy V, et al. Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: a single center analysis. Blood Cancer J. 2022;12:66.

Article  Google Scholar 

Shahi A, Weiss GE, Bhattacharya S, Baiu DC, Marino R, Pula T, et al. Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical. Leuk Lymphoma. 2021;62:1518–21.

CAS  Article  Google Scholar 

Lubner SJ, Mullvain J, Perlman S, Pishvaian M, Mortimer J, Oliver K, et al. A phase 1, multi-center, open-label, dose-escalation study of 131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies. Cancer Investig. 2015;33:483–9.

CAS  Article  Google Scholar 

Ailawadhi S, Stiff P, Ibrahim E, Vallurupalli A, Cull E, Green D. et al. Fractionated dosing of CLR 131 in patients with relapsed or refractory multiple myeloma (RRMM). Blood. 2019;134(suppl 1):144.

Article  Google Scholar 

Kumar S, Paiva B, Durie B, Rajkumar SV, San Miguel J, Avet-Loiseau H, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

Article  Google Scholar 

Gregory T, Cohen AD, Costello CL, Abbas Ali S, Berdeja JG, Ostertag EM. et al. Efficacy and safety of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM). Blood. 2018;132(suppl 1):1012.

Article  Google Scholar 

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.

CAS  Article  Google Scholar 

Chari A, Vogl DT, Gavriatopoulou AK, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727–38.

CAS  Article  Google Scholar 

Zhao W-H, Liu J, Wang B-Y, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141.

CAS  Article  Google Scholar